Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis

Medical Oncology

Volumn 31, Issue 9, 2014, Pages 1-9

  Liu, Peng Fei ^a   Cao, Yan Wei ^a   Jiang, Hai Ping ^a   Wang, Yong Hua ^a   Yang, Xue Cheng ^a   Wang, Xin Sheng ^a   Niu, Hai Tao ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Biological pathway; Biomarker; Heterogeneity; iTRAQ; Muscle invasive bladder cancer; Proteomics

Indexed keywords

EID: 84905289629     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0021-9     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
3. Niu H, Jiang H, Cheng B, Li X, Dong Q, Shao L, et al. Stromal proteome expression profile and muscle-invasive bladder cancer research. Cancer Cell Int. 2012;12(1):39.
4. De Sousa EMF, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity–a multifaceted view. EMBO Rep. 2013;14(8):686–95.
5. Tong W, Harris S, Cao X, Fang H, Shi L, Sun H, et al. Development of public toxicogenomics software for microarray data management and analysis. Mutat Res. 2004;549(1–2):241–53.
6. Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab. 2013;304(8):E789–99.
7. Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013;109(1):14–23.
8. Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007;67(7):3345–55.
9. Yuan Q, Wang M, Wang M, Zhang Z, Zhang W. Macrophage migration inhibitory factor gene −173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis. Mol Biol Rep. 2012;39(3):3109–15.
10. Li M, Shen J, Wu X, Zhang B, Zhang R, Weng H, et al. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol. 2013;30(2):587.
11. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG. Targeting glucose metabolism: an emerging concept for anticancer therapy. Am J Clin Oncol. 2011;34(6):628–35.
12. Zaidel-Bar R, Itzkovitz S, Ma’Ayan A, Iyengar R, Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol. 2007;9(8):858–67.
13. Seong KM, Jung SO, Kim HD, Kim HJ, Jung YJ, Choi SY, et al. Yeast ribosomal protein S3 possesses a beta-lyase activity on damaged DNA. FEBS Lett. 2012;586(4):356–61.
14. Li C, Ge M, Yin Y, Luo M, Chen D. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Mol Cell Biochem. 2012;370(1–2):127–39.
15. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005;123(1):49–63.
16. Lan YJ, Chen H, Chen JQ, Lei QH, Zheng M, Shao ZR. Immunolocalization of Vimentin, Keratin 17, Ki-67, Involucrin, beta-Catenin and E-Cadherin in cutaneous squamous cell carcinoma. Pathol Oncol Res. 2013;20(2):263–6.
17. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
18. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009;15(1):22–9.
19. Levett D, Flecknell PA, Rudland PS, Barraclough R, Neal DE, Mellon JK, et al. Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am J Pathol. 2002;160(2):693–700.
20. Matsumoto K, Irie A, Satoh T, Ishii J, Iwabuchi K, Iwamura M, et al. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 2007;70(3):602–7.
21. Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S et al. FOXM1 Promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014:20(10):2595–606.
22. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53(4):233–56.
23. Yao F, Zhao T, Zhong C, Zhu J, Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013;34(1):25–31.
24. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life. 2013;65(11):904–10.